Large U.S. CRE Deals Make a Powerful Comeback in Q3 2025

City skyline sunrise

After a sluggish start to 2025, the commercial real estate world finally exhaled. According to new research from Altus Group, large single‑asset CRE deals — those valued above $10 million — surged back to life in Q3 2025. With more than $76 billion in transactions, this quarter delivered the most impressive rebound in over a decade, signaling a renewed sense of investor confidence across the country.

For real estate professionals, investors, and emerging industry leaders (including many developing their expertise at Cameron Academy), this resurgence provides a clear message: capital is flowing again — and at scale.

Source Highlight: Dive deeper into the full market findings at Altus Group: Q3 2025 CRE Investment & Transactions Report

The Return of the Major Deal

For the first time in several quarters, both annual and quarterly traded‑property counts saw meaningful increases. But the true headline lies in which deals made their comeback. Large single‑asset transactions roared back, totaling 1,826 trades above $10 million — the highest since Q3 2022.

These big‑ticket trades accounted for 67.8% of all single‑asset dollar volume, a level not reached since mid‑2022 and slightly surpassing the highs of late 2018. In short: major players are re‑entering the market.

How Big Was the Rebound?

Large-deal momentum surged across every measurable metric:

  • Up 48% quarter‑over‑quarter
  • Up 41% year‑over‑year
  • Up 15.9% on a trailing four‑quarter basis

This represents the most robust growth in large‑asset trading since 2015 (excluding the unusual post‑pandemic surge).

Why Overall Volume Still Lags 2021–2022 Highs

Even with the resurgence, total transaction volume hasn’t quite matched the peaks of 2021 and early 2022 — primarily because median deal sizes remain smaller. The median large CRE deal in Q3 2025 landed at $19.6 million, roughly 9% below the late‑2021 cycle peak.

Sector‑specific breakdown reveals even more nuance:

  • Industrial: $18.9M (1.7% below peak)
  • Multifamily: $29.3M (8.2% below peak)
  • Retail: $15.5M (6.1% below peak)
  • Office: $18.1M (23.8% below peak — still the market laggard)

However, the median large‑deal size has climbed a solid 4.7% since its post‑pandemic low in late 2023, with multifamily leading the recovery.

Pricing Trends and Stabilization

The median price per square foot improved modestly across most property types, increasing 0.6% quarter‑over‑quarter and year‑over‑year. Office properties continued to face pressure, declining 3% on the quarter and 4.4% annually, while multifamily assets posted a healthy 5% annual increase.

A Step Toward Normalcy

The return of large single‑asset CRE transactions signals more than volume: it represents a renewed sense of investor certainty, clearer pricing expectations, and strengthened liquidity at the top of the market.

As the year wraps up, one question looms: Is this the start of a sustained recovery — or simply a temporary surge before the next slowdown?

Regardless, Q3 2025 stands as the most convincing evidence in years that the upper tier of the CRE landscape is regaining its footing — excellent news for brokers, lenders, investors, and professionals preparing for future opportunities.

For complete datasets, visualizations, and sector‑by‑sector deep dives, visit the full Altus Group quarterly analysis:
US CRE Investment & Transactions Report

Professionals seeking to stay sharp as the market evolves can elevate their credentials and readiness through Cameron Academy — Florida’s trusted destination for real estate education, professional licensing, and continuing education across dozens of industries nationwide.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

The Transformation of Insurance Through Customer-Centric Ecosystems

In the fast-evolving world of insurance, a transformative shift is underway, driven by the development of customer-centric ecosystems. As highlighted in a comprehensive study by EY, insurance ecosystems are reshaping the industry by focusing on customer engagement, trust, and operational excellence.

Ethical Challenges of AI in Radiography: Insights from Radiographers

The integration of artificial intelligence in radiography brings a host of ethical challenges that demand careful consideration. A recent study highlights the diverse perspectives of radiographers, revealing significant knowledge gaps and varying trust levels in AI-driven decisions. Concerns over patient privacy and the need for dedicated ethical guidelines are pivotal as healthcare embraces AI.

AI in Healthcare: A Transformative Force Today and Tomorrow

AI tools are already delivering significant value and are poised to further transform healthcare. Embracing these changes today will position organizations and individuals to capture the long-term benefits of a more effective, efficient, and personalized healthcare system.

2024 Housing Market Crystal Ball: Transformative Trends for the Next Decade

The housing landscape of 2034 will be more diverse, technologically advanced, and responsive to the needs of an evolving population.

The Future of AI in Pathology: A Market on the Rise

AI in pathology is revolutionizing the field by enhancing the analysis of clinical data, genomic information, and disease progression. These advancements are not only streamlining personalized treatment plans but also optimizing healthcare resource allocation.

By |January 12, 2025|Categories: Article, Healthcare, Technology|Tags: , |0 Comments

Revolutionizing Precision Medicine: AI’s Role in Diabetes and Chronic Disease Management

In an era where data reigns supreme, the integration of artificial intelligence (AI) and machine learning (ML) into the realm of precision medicine is not just a possibility but a burgeoning reality.